Harvard University’s Office of Technology Development (OTD) announced on October 15, 2026, a new licensing framework called ExpressPath, designed to let startups license Harvard-developed engineering, medical-device, and software technologies without the months-long negotiation process that has long been a bottleneck for university spinouts. The announcement positions Harvard among a small group of research universities rethinking how academic intellectual property reaches the commercial market, at a moment when AI hardware, robotics, and advanced-materials startups are racing to get products out the door before funding windows close.
According to Harvard OTD, ExpressPath uses pre-set, market-rate financial terms paired with a simplified license agreement, cutting out the back-and-forth that typically defines university tech-transfer deals. OTD publishes those terms, along with the license agreement for each pathway, on its ExpressPath pages. The office says the model can shrink negotiations that can take more than six months and involve tens of thousands of dollars in legal fees “into a matter of weeks, if not less time.”
Don't miss new tech stories on Google
Add Tech Insider once in the Google app and our stories appear in your news suggestions.
What ExpressPath Actually Changes for Startups
The core shift is procedural rather than financial in the sense that Harvard is not giving technology away for free. Instead, OTD has fixed the business terms in advance, from equity and royalty rates to sublicense and maintenance fees, at what the office describes as market rates, and it does not negotiate them. A founding team that qualifies for ExpressPath can skip the custom-negotiation phase altogether and sign a standard license agreement. That is the detail that matters most to early-stage founders, who often burn precious runway paying patent attorneys to haggle over terms before they have even incorporated a company.
Harvard’s Senior Vice Provost for Research, John Shaw, framed the goal in the announcement: “By reducing uncertainty and creating a clear path to commercialization, we can help researchers, founders, and investors move promising innovations forward more effectively and at a faster pace.” Sam Liss, OTD’s chief technology development officer and associate provost, was blunter: “Simply put, ExpressPath removes the haggling.” That framing matters because tech-transfer offices are frequently accused of acting as a drag on innovation rather than an enabler of it. A fixed-term, fast-track license directly answers that criticism, at least for the categories of technology ExpressPath covers.
Three Pathways, Three Very Different Technology Categories
ExpressPath is not a single license template. Harvard OTD split the program into three distinct pathways, each tuned to the kind of technology and startup team involved:
- Engineering & Tech ExpressPath License: covers instruments, quantum technologies, advanced materials, coatings, hardware, electronics, AI algorithms, robotics, energy, environmental technologies, and other physical-science innovations.
- Medical Device ExpressPath License: covers devices used in healthcare, explicitly excluding traditional therapeutics and biologics, which remain on Harvard’s traditional, negotiated licensing track.
- Software ExpressPath License: offers two options. A startup whose code has not been released under a permissive open-source license can take an exclusive license of the code base, while a startup built on code already released under a permissive open-source license can receive a “good standing” letter from Harvard instead.
The breadth of the engineering and technology pathway is the detail worth sitting with. Quantum technologies, advanced materials, coatings, robotics, and AI algorithms do not usually move at the same commercialization speed. A coatings patent might sit dormant in a lab notebook for years before anyone builds a company around it, while an AI algorithm developed this semester could be the backbone of a funding round within months. By grouping all of these hardware-adjacent categories under one fast-track license, Harvard is betting that standardized terms can work across wildly different technology-readiness levels, something that has historically been the argument for keeping negotiations case-by-case.
ExpressPath’s Three Pathways at a Glance
| Pathway | Scope | Notable Exclusions or Structure |
|---|---|---|
| Engineering & Tech ExpressPath License | Instruments, quantum technologies, advanced materials, coatings, hardware, electronics, AI algorithms, robotics, energy and environmental technologies | Broadest of the three pathways; spans physical-science and AI-hardware categories |
| Medical Device ExpressPath License | Devices used in healthcare | Excludes traditional therapeutics and biologics, which stay on Harvard’s traditional licensing track |
| Software ExpressPath License | Software technologies | Two options: an exclusive license of the code base, or a “good standing” letter for code already released under a permissive open-source license |
The Problem ExpressPath Is Trying to Solve
University technology licensing has a well-documented speed problem. Harvard’s own characterization of the status quo, that a conventional negotiation can run past six months and cost tens of thousands of dollars in legal fees, lines up with what founders in university-spinout ecosystems have complained about for years at MIT, Stanford, and other major research institutions. For a hardware or AI startup trying to close a seed round, six months of legal limbo can mean missing a product cycle entirely, or watching a competitor without university IP obligations ship first.
That delay is especially costly for engineering and AI-hardware startups, where component sourcing, chip fabrication slots, and investor terms are frequently time-boxed. A startup negotiating a license for a sensor platform or a robotics control algorithm does not just lose months on paperwork, it can lose its place in a supply chain queue or its most interested lead investor. Harvard’s pitch is that ExpressPath removes that specific failure mode for technologies that fall within its three defined pathways.
Harvard’s Existing Licensing Footprint
Context matters here. Harvard OTD’s homepage lists 970 active technology licenses with more than 670 industry collaborators, along with 90 startups in five years. Those figures describe Harvard’s entire licensing portfolio, not ExpressPath: not all of those licenses are with startups, and not all of them fall within ExpressPath’s three areas of Engineering & Tech, Medical Device and Software. ExpressPath adds a pre-set option for eligible startups; those that need tailored terms can still pursue a traditional, negotiated license. The practical question the tech-transfer community will be watching in the coming months is what share of new startup licenses route through ExpressPath versus the traditional process. The October 15 announcement did not set a volume target.
The ExpressPath terms themselves are public. OTD publishes the financial terms and the license agreement for each pathway on its ExpressPath pages, which it says gives founders and investors “predictable expectations” and ensures “similar startups are treated consistently.” The key numbers are set out in the terms table below.
Why This Lands in the Hardware and Deep-Tech Category
While ExpressPath spans software and medical devices too, the program’s center of gravity sits squarely in hardware and physical-science commercialization. Quantum computing components, advanced coatings, robotics platforms, and AI-accelerator-adjacent instrumentation are exactly the categories where a university’s intellectual property sits closest to a chip, a sensor, or a physical prototype rather than a line of code. For founders building hardware-dependent AI systems, robotics platforms, or energy technologies, a predictable, fast license is arguably more valuable than it is for a pure software spinout, because hardware startups face longer lead times on every other front: fabrication, testing, certification, and manufacturing partnerships.
That is also where ExpressPath’s timing intersects with the broader AI hardware cycle. 2026 has been defined by intense competition for AI accelerator capacity, with companies racing to secure fabrication slots and memory supply amid the ongoing HBM4 shortage and surging GPU prices. A university spinout building a novel AI chip architecture or a quantum-adjacent instrument cannot afford to lose months to legal negotiation while rivals, many backed by better-capitalized corporate labs, move faster. Harvard’s framing, that negotiations that can take more than six months can shrink to a matter of weeks, speaks directly to that competitive reality.
How ExpressPath Compares to Traditional University Licensing
| Factor | Traditional Harvard OTD License | Harvard ExpressPath License |
|---|---|---|
| Negotiation timeline | Can take more than six months | “A matter of weeks, if not less time” (OTD announcement); “days, rather than months” (OTD ExpressPath page) |
| Financial terms | Custom-negotiated per deal | Pre-set, market-rate terms, published for each pathway and not negotiated |
| Legal agreement | Fully customized contract | Simplified, standard license agreement, published online |
| Legal and upfront costs | Negotiations can involve tens of thousands of dollars in legal fees (Harvard OTD) | No negotiation phase, no upfront cash fees, and deferred patent cost reimbursement (Harvard OTD) |
| Technology scope | Any Harvard-owned IP, case by case | Three defined pathways: engineering/tech, medical devices (excluding therapeutics/biologics), software |
| Eligibility | Open to negotiation regardless of category | Harvard-affiliated startups commercializing Harvard-owned IP that fits one of the three pathways; OTD confirms eligibility and category |
Those terms are published. OTD posts the financial terms and the full license agreement for each pathway on its ExpressPath pages, and the October 15 announcement links to them. To develop the program, OTD says it reviewed hundreds of technology licenses at other U.S. universities and consulted investors and entrepreneurs, including MassVentures, to make sure they met fair market benchmarks.
ExpressPath’s Published Financial Terms
| Term | Engineering & Tech ExpressPath | Medical Device ExpressPath |
|---|---|---|
| Equity | 4% of the startup, or a 1% liquidation fee | 4% of the startup, or a 1% liquidation fee |
| Anti-dilution protection | Through the first $2.5M in outside funding | Through the first $2.5M in outside funding |
| Royalty | 2% with no royalty offset, or 3% with an offset for other IP the startup licenses | 2% with no royalty offset, or 3% with an offset for other IP the startup licenses |
| Sublicense revenue fee | 12% | 12% |
| Maintenance fee | $0 in years 1-3, $25K in years 4-5, $50K from year 6, creditable against royalties | $0 in years 1-3, $25K in years 4-5, $50K from year 6, creditable against royalties |
| Milestone payments | None | $400K per approval |
| Financing milestone | $750K in equity or convertible debt within 6 months of signing | $750K in equity or convertible debt within 6 months of signing |
| Back patent costs | Deferred for 1 year, accelerated at $2.5M raised | Deferred for 1 year, accelerated at $2.5M raised |
A startup organized as a limited liability company gets the fixed, non-dilutable 1% liquidation fee rather than equity. The Software ExpressPath works differently. Its exclusive license of the code base costs 2% equity, with anti-dilution protection through the first $2.5M raised, and carries no royalties or revenue-based fees. Its good standing letter, for startups built on code already released under a permissive open-source license, costs 1% equity, with anti-dilution protection through the first $1M raised, and carries no royalties, no revenue sharing and no ongoing reporting. The Engineering & Tech, Medical Device and Software exclusive licenses also let Harvard, or its assignee, invest up to 5% of initial financing rounds through $2.5M in cumulative funding.
Historical Context: Why Tech Transfer Has Been Slow
University technology-transfer offices emerged in their modern form largely after the 1980 Bayh-Dole Act, which gave American universities the right to patent and license federally funded research. That law created today’s tech-transfer ecosystem but also entrenched a negotiation-heavy culture: every license was treated as a bespoke deal between a university’s legal team and a startup’s counsel, with each side trying to optimize royalty rates, equity stakes, and field-of-use restrictions. Decades later, that same case-by-case approach is still the default at most research universities, even as the pace of startup formation in AI, robotics, and quantum computing has accelerated well beyond what a six-month negotiation cycle can reasonably accommodate.
Harvard is not the first university to experiment with simplified licensing. The University of North Carolina at Chapel Hill developed a standardized “express” startup license, the Carolina Express License Agreement, more than 15 years ago, and UC San Diego launched an Express License program with pre-determined terms in 2012. What distinguishes ExpressPath, based on Harvard’s own description, is the breadth of its engineering and technology pathway, spanning quantum technologies through robotics through AI algorithms, combined with a dedicated medical-device track and two software options. That is a wide net to cast in one announcement.
Market Impact: What This Means for Startup Formation
The immediate market effect of ExpressPath is hard to quantify until adoption numbers exist, and the October 15 announcement did not include any. But the directional impact is clearer. Faster, cheaper licensing lowers the barrier to spinning a Harvard lab discovery into a company, which should, over time, increase the number of startups formed around Harvard engineering and medical-device research. It should also shift negotiating leverage slightly toward founders and early investors, since a pre-set, market-rate deal removes the single biggest source of early-stage legal cost and uncertainty: not knowing what terms a university will eventually agree to.
For venture investors evaluating Harvard-affiliated deals, predictable terms also mean cleaner diligence. A term sheet built around a known licensing structure is easier to underwrite than one where the IP terms are still being hammered out in parallel with the funding round, a situation that has stalled or killed deals in the past when a university and an investor could not agree on royalty stacking or field-of-use language before a financing deadline.
Competitive Landscape: How Other Universities License Technology
Harvard’s announcement puts pressure on peer institutions to match the pace, even though exact comparisons are difficult without each university publishing equivalent fast-track terms. Some already offer pieces of the idea: MIT’s Technology Licensing Office has non-negotiable “expedited” licenses for some of its software, and UC San Diego’s Express License has offered pre-determined startup terms since 2012. If ExpressPath succeeds in measurably increasing Harvard spinout formation, it is reasonable to expect competing institutions to introduce comparable fast-track licenses, if only to avoid losing high-potential founders who might otherwise choose a university with faster IP terms when deciding where to commercialize dual-affiliated research.
What’s Not Yet Known
Harvard has published the core of the program: the financial terms, the license agreement and the eligibility guidance for each pathway. Its announcement also names the officials behind it, Senior Vice Provost for Research John Shaw and Sam Liss, OTD’s chief technology development officer and associate provost. What the October 15 announcement did not include is a count of startups that have signed an ExpressPath license so far, or a target for how many new licenses OTD expects to route through the program. OTD also says it will launch initiatives in the coming months to make it easier and clearer for industry to fund research in Harvard labs. Those are the details worth tracking next.
Five Predictions for ExpressPath’s Next 12 Months
- Peer universities respond within a year. Expect at least one major research university, such as MIT or Stanford, to announce a comparable multi-pathway startup licensing program within the next 12 months, framed explicitly as a response to competitive pressure from programs like ExpressPath.
- Software adoption outpaces hardware adoption early on. Because software IP typically carries fewer manufacturing and regulatory dependencies, the Software ExpressPath License is likely to see faster early uptake than the engineering/technology or medical-device pathways, where fabrication and compliance timelines remain a bottleneck regardless of how fast the license itself closes.
- Harvard will eventually publish adoption numbers. Expect Harvard OTD to release at least a rough count of ExpressPath-licensed startups within the next two to three quarters, likely timed to a fundraising announcement, an annual report, or a tech-transfer conference presentation.
- AI-hardware and robotics spinouts become the most visible beneficiaries. Given 2026’s intense competition for AI accelerator capacity and fabrication slots, startups in the engineering and technology pathway building AI algorithms, robotics, or advanced materials are the most likely group to publicly credit ExpressPath with helping them close financing or manufacturing deals faster.
- Medical-device exclusions will draw scrutiny. Because the medical-device pathway explicitly excludes traditional therapeutics and biologics, expect commentary from biotech-focused founders and investors questioning why the fastest licensing track does not extend to drug or biologic candidates, likely prompting Harvard to eventually clarify or expand that boundary.
What Founders Should Do Now
For researchers and founders with Harvard-affiliated IP, the practical next step is straightforward: contact Harvard OTD directly to determine whether a specific technology qualifies for one of the three ExpressPath pathways before engaging outside patent counsel for a traditional negotiation. OTD publishes eligibility guidance on its ExpressPath pages, including who is generally eligible (startups founded by Harvard faculty, postdocs, graduate students or recent alumni, incorporated in the U.S. and focused on commercializing Harvard-owned IP) and what may rule a case out, such as IP jointly owned with other institutions. Because OTD confirms eligibility and assigns the pathway itself, a direct conversation with the office is still the fastest way to a definitive answer.
Investors evaluating Harvard-affiliated deals should likewise ask founders early whether a given license falls under ExpressPath or the traditional process, since that single detail now materially changes the expected closing timeline and legal cost exposure for the deal.
The Bigger Picture for University Tech Transfer
ExpressPath arrives at a moment when the broader AI and hardware funding environment is unusually fast-moving and unusually competitive, with chip shortages, AI capex surges, and compressed product cycles all rewarding startups that can move from lab bench to market with minimal friction. A university licensing office that can genuinely compress a six-month negotiation into a few weeks is addressing one of the most persistent complaints in academic entrepreneurship. Whether ExpressPath delivers on that promise at scale, across quantum technologies, robotics, AI algorithms, medical devices, and software alike, will depend on what no announcement can settle: real adoption figures, and whether eligible founders find the process as fast as advertised.
The announcement itself, published by Harvard’s Office of Technology Development on October 15, 2026 and distributed through EurekAlert, marks a genuine shift in how one of the world’s best-funded research universities intends to move its hardware, software, and medical-device discoveries into the commercial market. The next real test comes when the first wave of ExpressPath-licensed startups starts showing up in funding announcements and product launches.
Frequently Asked Questions
What is Harvard ExpressPath?
ExpressPath is a new licensing model from Harvard’s Office of Technology Development that uses pre-set, published, market-rate financial terms and a simplified license agreement so eligible Harvard-affiliated startups can license Harvard engineering, medical-device, or software technologies without a lengthy custom negotiation.
How long does an ExpressPath license take compared to a traditional license?
Harvard OTD says eligible teams can execute an ExpressPath license in a matter of weeks, if not less time, compared to conventional negotiations that the office says can take more than six months and involve tens of thousands of dollars in legal fees. OTD’s ExpressPath page says licenses can be completed “in days, rather than months.”
What technologies are covered under ExpressPath?
Three pathways: the Engineering & Tech ExpressPath License, covering instruments, quantum technologies, advanced materials, coatings, hardware, electronics, AI algorithms, robotics, and energy and environmental technologies; the Medical Device ExpressPath License, covering devices used in healthcare but excluding traditional therapeutics and biologics; and the Software ExpressPath License, which offers either an exclusive license of the code base or, for code already released under a permissive open-source license, a good standing letter.
Does ExpressPath replace Harvard’s traditional licensing process?
No. ExpressPath is an additional fast-track option for technologies and startup teams that fit its three defined pathways. Harvard’s traditional, negotiated licensing process remains in place for deals outside those categories, including therapeutics and biologics.
How many active technology licenses does Harvard currently have?
Harvard OTD’s homepage lists 970 active technology licenses with more than 670 industry collaborators. That figure covers Harvard’s entire licensing portfolio, not ExpressPath: not all of those licenses are with startups or fall within ExpressPath’s three areas.
Has Harvard published specific ExpressPath royalty rates or equity terms?
Yes. OTD publishes the financial terms and the license agreement for each pathway on its website. The Engineering & Tech and Medical Device licenses carry 4% equity (or a 1% liquidation fee), a 2% royalty (or 3% with an offset for other IP the startup licenses) and a 12% sublicense revenue fee. The Software exclusive license carries 2% equity and no royalties, and the Software good standing letter carries 1% equity and no royalties.
Will other universities adopt a similar fast-track licensing model?
Harvard has not announced any coordination with other universities on ExpressPath, although OTD says it reviewed hundreds of technology licenses at other U.S. universities to set the terms. However, competitive pressure in AI, robotics, and hardware startup formation makes it plausible that peer research universities will introduce comparable fast-track licensing programs if ExpressPath demonstrably speeds up Harvard spinout formation.
Who should contact Harvard OTD about ExpressPath eligibility?
Researchers and founders working with Harvard-affiliated engineering, medical-device, or software technology should contact Harvard’s Office of Technology Development directly to determine whether their specific technology qualifies for one of the three ExpressPath pathways before pursuing a traditional license negotiation.
Related Coverage
- Las Vegas Tesla Arsonist Gets 5 Years, Not 20 [2026]
- Nvidia DLSS 5 Update: 2x Faster Model, 20% Less VRAM [2026]
- Rocket Lab Slips Neutron Debut to 2027 on Dome Flaw [2026]
- TECNO Spark 50s 5G India Debut: 2 Colors, Oct. 16 [2026]
- Set Up ROG Xbox Ally X20: 13 Steps, 120Hz OLED [2026]
